FDA to decide how to regulate CBD in months
The U.S. Food and Drug Administration is planning to make recommendations on how to regulate the use of the popular marijuana compound cannabidiol (CBD) in foods and supplements, the Wall Street Journal reported, citing agency officials.
After weighing the evidence about the compound's safety, the FDA will decide within months how to regulate CBD and whether that will require new agency rules or new legislation from Congress, the report said.
In an interview, Janet Woodcock, FDA deputy commissioner and head of cannabis regulatory efforts, expressed concern about the safety of CBD and whether the current regulatory pathway for food and dietary supplements applies to the substance.
However, the agency is interested in determining whether it is safe to consume CBD daily for extended periods of time or during pregnancy.
Woodcock cited concerns about the potential impact on future fertility, but at the same time, her comments suggest that the agency is working to establish a regulatory framework to legally market appropriate cannabis and cannabis-derived products.
CBD is a compound found in the cannabis plant. It's one of the main ingredients in cannabis, but unlike THC, it doesn't cause highs or produce psychoactive effects.
The 2018 Farm Bill legalized the cultivation of hemp in the United States, which has led to significant growth in the market for CBD products. These products are sold as dietary supplements and are believed to have health benefits. As a result, many businesses in the cannabis industry are now selling CBD products nationwide across the United States.
Over the past few years, the FDA has issued several warning letters to companies illegally marketing products containing CBD. The companies have been accused of selling products that contain CBD, which the FDA says some people may confuse with conventional foods or beverages that do not contain CBD, or make medical claims about their CBD products.
In 2021, the FDA told Charlotte's Web Holdings, one of the world's largest CBD companies, that its cannabidiol products could not be marketed as dietary supplements, suggesting that CBD reform may have to wait for Congressional action.
Email:sales@mlifevapor.com
WhatsApp:+86 13871529372
Email:sales@mlifevapor.com
WhatsApp:+86 13871529372
Tel：+86 13871529372
Add：6 / F, block B, building 2, Fuyong Tongtai times center, Bao'an District, Shenzhen
Copyright © 2008-2022 Shenzhen Mlife Technology Co., Ltd. All Rights Reserved
Language： 简体中文 | >
Copyright © 2008-2022 Shenzhen Mlife Technology Co., Ltd. All Rights Reserved
Tel：+86 13871529372
Add：6 / F, block B, building 2, Fuyong Tongtai times center, Bao'an District, Shenzhen Website
